AMSBIO has further expanded its product range to help in the fight against COVID-19 with the introduction of a new range of SARS-CoV-2 antibodies and antigens to aid development of new immunoassay diagnostic kits.

While RT-PCR diagnostic kits has provided fast and sensitive COVID-19 case confirmation, the technique suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To facilitate rapid screening and instant detection of SARS-CoV-2 infection, development of faster and convenient antibody and antigen-based immunoassays are essential. However, the sensitivity and specificity of these serological diagnostic kits will be significantly affected by the quality of antigen and antibody reagents used to make them.

A suite of SARS-CoV-2 mutant spike and nucleocapsid antigens is now available from AMSBIO. Perfect for use in a wide range of different antibody detection methods, these antigens are customizable and available in bulk. In addition, AMSBIO has also introduced a new range of matched antibody pairs that were specifically designed and screened for antigen detection kit development. Verified against inactivated COVID-19 virus samples, these antibody pairs are ideal for development of diagnostic assays including chemiluminescent immunoassay, ELISA and gold immunochromatography (also known as lateral flow). The sensitivity of these matched antibody pairs used in a sandwich ELISA kit has been shown to be as low as 12pg/mL. The virus titer, which was determined using a LFA assay, is as low as 102CCID50.

To learn more about AMSBIO’s extensive range of tools to kickstart your Coronavirus research including proteins, inhibitor screening kits, antibodies, lentivirus, an IgG/IgM rapid test kit and more please visit www.amsbio.com/covid-19.

For further information on the new SARS-CoV-2 antibodies and antigens range please visit https://www.amsbio.com/antibodies-antigens-sars-cov-2-diagnostic-kits or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology.

< | >